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Abstract
Introduction Decreased vascular responses to salivary gland
stimulation are observed in Sjögren's syndrome patients. We
investigate whether impaired vascular responses to
parasympathetic stimulation and muscarinic receptor activation
in salivary glands parallels hyposalivation in an experimental
model for Sjögren's syndrome.
Methods Blood flow responses in the salivary glands were
measured by laser Doppler flowmeter. Muscarinic receptor
activation was followed by saliva secretion measurements. Nitric
oxide synthesis-mediated blood flow responses were studied
after administration of a nitric oxide synthase inhibitor. Glandular
autonomic nerves and muscarinic 3 receptor distributions were
also investigated.
Results Maximal blood flow responses to parasympathetic
stimulation and muscarinic receptor activation were significantly
lower in nonobese diabetic (NOD) mice compared with BALB/
c mice, coinciding with impaired saliva secretion in nonobese
diabetic mice (P < 0.005). Nitric oxide synthase inhibitor had
less effect on blood flow responses after parasympathetic nerve
stimulation in nonobese diabetic mice compared with BALB/c
mice (P < 0.02). In nonobese diabetic mice, salivary gland
parasympathetic nerve fibres were absent in areas of focal
infiltrates. Muscarinic 3 receptor might be localized in the blood
vessel walls of salivary glands.
Conclusions Impaired vasodilatation in response to
parasympathetic nerve stimulation and muscarinic receptor
activation may contribute to hyposalivation observed in
nonobese diabetic mice. Reduced nitric oxide signalling after
parasympathetic nerve stimulation may contribute in part to the
impaired blood flow responses. The possibility of muscarinic 3
receptor in the vasculature supports the notion that muscarinic
3 receptor autoantibodies present in nonobese diabetic mice
might impair the fluid transport required for salivation.
Parasympathetic nerves were absent in areas of focal infiltrates,
whereas a normal distribution was found within glandular
epithelium.
Trial registration The trial registration number for the present
study is 79-04/BBB, given by the Norwegian State Commission
for Laboratory Animals.
Introduction
Sjögren's syndrome (SS) is a systemic autoimmune disease
mainly affecting the exocrine glands, resulting in severe impair-
ment of saliva and tear production. The histopathological hall-
marks of the disease are T-cell-dominated and B-cell-
dominated focal infiltrates in the salivary glands. It has been
suggested that the decrease in salivary flow follows the occur-
rence of focal lymphoid infiltration, with a considerable delay inPage 1 of 12
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tissue by inflammatory cells is not sufficient to explain the
severe impairment in salivary secretion [1]. The unclear inter-
relationship between glandular inflammation and hyposaliva-
tion [2,3] has led to research initiatives investigating
mechanisms of glandular dysfunction. Autoantibodies inhibit-
ing receptors for neurotransmitter receptors and defective
water transport have been proposed [4]. In the salivary glands,
blood flow and salivary secretion are under autonomic nervous
control of both parasympathetic and sympathetic nerves [5].
During salivation, fluid is transported from the capillaries
through the interstitial space, before being secreted by the
glandular epithelium [6].
The nonobese diabetic (NOD) mouse strain exhibits immuno-
logical, histopathological and physiological characteristics of
SS with focal mononuclear cell infiltration of the exocrine
glands from approximately 8 weeks of age [7]. The manifesta-
tions of overt SS hallmarked by impaired lacrimal and salivary
secretion are thought to develop later in life [1]. In the NOD
mice, no augmentation of saliva flow rates has been observed
after infusion of neuropeptides combined with muscarinic–
cholinergic agonist [8], indicating that the hyposalivation
observed in NOD mice may, at least in part, be due to a gen-
eral loss of neurotransmitter responsiveness in salivary glands.
On the other hand, an in vitro study on human labial gland cells
isolated from patients with primary SS has demonstrated sim-
ilar response to stimulation with acetylcholine and neuropep-
tides as healthy controls, indicating functional receptor
systems [9]. Whether the loss of responsiveness in vivo is
located on the vascular side or is related to circulating autoan-
tibodies affecting receptor function is unknown.
Changes in receptor expression such as a downregulation of
β-adrenergic receptors and their signal transduction response
[10], as well as a downregulation of muscarinic receptors [11]
and the presence of autoantibodies against muscarinic 3
receptors (M3Rs), have been described in the NOD mice [12].
In contrast, an upregulation of the M3R has been demon-
strated in labial salivary gland tissue from patients with SS
[13].
Nitric oxide (NO) signalling is activated through muscarinic
receptors in the salivary glands [14,15], and NO synthase
activity and expression are reported to be decreased in NOD
mice [16] – supporting the hypothesis of an impaired neural
regulation in the salivary glands in NOD mice. Impaired neuro-
transmitter release in salivary glands in the MRL/lpr mouse,
another murine model of SS, has also been reported [17].
Patients with SS have elevated salivary levels of vasoactive
intestinal peptide (VIP) and neuropeptide Y (NPY), which are
mainly found in parasympathetic and sympathetic nerves,
respectively. This finding indicates increased release of VIP
and NPY by salivary glands of SS patients [18].
As both vessels and epithelial cells are equipped with mus-
carinic and adrenergic receptors, and are innervated by auto-
nomic nerves, we hypothesized that the vascular responses to
autonomic stimulation may be reduced in the NOD mice. To
test this hypothesis, we measured changes in blood flow in the
submandibular gland in the response to parasympathetic stim-
ulation in NOD mice, and investigated the contribution of NO
to the observed vasodilatation. Furthermore, we measured
blood flow responses after muscarinic activation with a simul-
taneous effect on salivation, and verified the presence of M3R
in the wall of blood vessels in the submandibular gland. As
potential changes in the autonomic innervation pattern in NOD
mice may be directly related to the observed alterations, immu-
nohistochemical detection of both parasympathetic and sym-
pathetic nerves as well as glandular inflammation were
included in this study.
Materials and methods
Animals
Female NOD mice and BALB/c mice were purchased from
Taconic Bomholtgård, (Ry, Denmark) (n = 22 + 22) and from
Jackson Laboratories (Bar Harbor, Maine, USA) (n = 7 + 7),
and were kept under standard animal housing conditions at
the animal facility of the Department of Biomedicine, University
of Bergen, Norway. The experiments were carried out with the
approval of the Norwegian State Commission for Laboratory
Animals and were approved by the local ethical committee.
The 16-week-old to 18-week-old BALB/c mice and NOD mice
were anaesthetized with Hypnorm-Dormicum 0.5 ml/10 g
body weight (BW) (Janssen Pharmaceutical, Beerse, Bel-
gium). Pilocarpine hydrochloride and Nω-nitro-L-arginine-
methyl ester (L-NAME) were purchased from Sigma Chemical
Co. (St Louis, MO, USA). Two strains of mice were used in this
study since Taconic stopped their breeding of NOD mice dur-
ing the experimental period.
Blood flow recordings
The BALB/c mice and NOD mice from Taconic (Group 1, n =
10 + 10) and from Jackson Laboratories (Group 2, n = 7 + 7)
(Table 1) were studied in a supine position, and the body tem-
perature was kept at 37 to 38°C with a servocontrolled heat-
ing pad. A femoral artery was catheterized for continuous
systemic blood pressure recordings with a Gould pressure
transducer and recorder, and a submandibular gland dis-
sected free. In 10 BALB/c mice and 10 NOD mice (Group 1),
the submandibular duct comprising the lingual nerve with par-
asympathetic fibres from chorda tympani was placed on an
electrode and stimulated electrically. The submandibular
gland was chosen since this gland is encapsulated and its
main excretory duct easily isolated, thus allowing parasympa-
thetic nerve stimulation. Electrical stimulation was performed
with a Grass stimulator (Quincy, MA, USA), giving square
wave pulses of 2 milliseconds at 7 Hz; 8 V for periods of 2 to
5 seconds.Page 2 of 12
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imed KB, Järfälla, Sweden) equipped with a needle probe PF
415:10 (fibre diameter 125 μm, with separation 500 μm) was
used to measure changes in glandular blood flow in all animals
(Group 1 and Group 2). Zero blood flow was calibrated in a
zeroing disc and by use of a motility standard giving an output
value of 250 perfusion units (PU). We carried out standard cal-
ibration of the instruments and fibre-optic probes according to
the manufacturer's specifications. The laser probe was posi-
tioned with a micromanipulator above the gland on the anterior
middle part of the gland and was rotated to the position that
gave the largest resting blood flow signal measured in arbitrary
PU. The flowmeter set constant was 0.03 and the lower band-
width was at 20 kHz and at 20 Hz, respectively. All data were
stored and analysed using Perisoft computer software
(Perisoft 2.1; Järfälla, Sweden).
After one stimulation period (Group 1), a NO synthesis blocker
(L-NAME, 90 mg/kg BW) was diluted in 0.05 ml of 0.9% saline
and was infused intravenously over a period of 1 minute. Elec-
trical stimulation was repeated 2 to 3 minutes after the end of
infusion.
In Group 2 pilocarpine (0.10 mg/100 g BW dissolved in 0.01
ml of 0.9% saline) was infused over 1 minute and the glandular
blood flow changes were recorded simultaneously as saliva
was collected from the oral cavity into preweighed tubes for
10 minutes (Table 1). This dose was chosen since it has been
demonstrated to give reproducible blood flow responses in rat
submandibular glands [19]. Measurements of blood flow and
systemic blood pressure were measured continuously before,
during and after infusions in all animals. After pilocarpine
responses were measured and saliva collected, the sub-
mandibular gland used for blood flow measurement was
removed and fixed in 10% buffered formalin and the contralat-
eral gland was snap-frozen in liquid nitrogen by isopentane.
The blood glucose level was tested with blood samples
obtained by tail vein puncture before the start of blood flow
measurements.
Stimulated salivary flow measurement
The saliva secretion capacity in response to muscarinic recep-
tor stimulation was assessed in six Balb/c mice and six NOD
mice (Taconic; see Table 1) after being fasted for a minimum
of 5 hours with water ad libitum. Subsequent to intraperitoneal
injection of 0.05 mg/100 g BW pilocarpine (dissolved in 0.01
ml of 0.9% saline), saliva was collected from the oral cavity
with 20 μl micropipettes for 10 minutes. To prevent asphyxia-
tion, mice were held upright with the tongue extended by a for-
ceps during the experiment [3]. The results are expressed in
microlitres of saliva per minute per gram of BW.
Assessment of hyperglycaemia
NOD mice and the age-matched BALB/c from Taconic were
assessed for hyperglycemia using a Reflotron Plus Glucose
test kit (Roche Diagnostics, Quebec, Montreal, Canada) and
from Jackson Laboratories (Group 2) using the Keto-diabur
test 5000 (Roche, Meylan, France). NOD mice with glucose
levels higher than 11 mmol/l were considered hyperglycaemic
and were excluded from the study [20]. The glucose levels in
experimental animals from Taconic and Jackson Laboratories
ranged between 3.4 and 8.5 mmol/l and 2.5 mmol/l and 8.2
mmol/l, respectively.
Immunofluorescence
Salivary gland sections (6 μm) from Group 2 animals (Table 1)
were incubated overnight with polyclonal antibody to M3R
(Santa Cruz Technology, Santa Cruz, California, USA) (for
antibody specificity, see [21]) and with CD31 monoclonal anti-
body (Serotec, Kidlington, UK), to test whether M3Rs were
localized in salivary gland blood vessels. CD31 was used as a
panendothelial marker. The secondary antibodies used were
Cy3 conjugated goat-anti rabbit (Jackson Immuno Research,
Baltimore, MD, USA) and Alexa Fluor Gold 488 conjugated
goat anti-rat (Molecular Probes, Invitrogen, Paisley, UK). The
sections were evaluated in a fluorescence microscope (Zeiss
Axio Imager HBO 100; Carl Zeiss MicroImaging Inc., Jena,
Germany).
Table 1
Distribution of nonobese diabetic (NOD) mice and BALB/c mice used










10 + 10 4 + 4 20
Jackson Laboratories 
(Group 2)
7 + 7 7 + 7 7 + 7 7 + 7 14
Taconic Bomholtgård 6 + 5a 11
Taconic Bomholtgård 6 + 6 6 + 6 12
Total 34 25 34 26 57
Data presented as number of mice. aOne BABL/c mouse was lost during salivary stimulation.Page 3 of 12
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Six NOD mice and six BALB/c mice (Taconic; see Table 1)
were anaesthetized as described above and were transcardi-
acally perfused with heparinized saline followed by fixative (4%
paraformaldehyde with 0.2% picric acid in 0.1 M phosphate
buffer, pH 7.4). The submandibular glands were excised and
post-fixed for 2 hours. After cryoprotection with 30% sucrose,
the glands were stored at -80°C until sectioning.
Alternate cryostat serial sections (30 μm) of the glands were
processed for immunohistochemistry on precoated glass
slides (SuperFrost Plus; Menzel-Glaser, Braunschweig, Ger-
many). For staining of sympathetic and parasympathetic nerve
fibres, alternate serial sections were incubated for 72 hours
either with polyclonal rabbit anti-NPY antibody (1:4,000 dilu-
tion; Peninsula Laboratories Inc., San Carlos, California, USA)
or with polyclonal rabbit anti-VIP antibody (1:5,000 dilution;
Eurodiagnostica, Malmö, Sweden). The sections were rinsed
in PBS and treated with 0.3% hydrogen peroxide in absolute
methanol.
Sections for NPY labelling were incubated in 2.5% normal
goat serum (Vector Ltd., Burlingam, CA, USA) for 1 hour,
before NPY antibody (1:4,000) was incubated with 2.5% nor-
mal goat serum for 72 hours at 4°C. After several rinses in
PBS, sections were incubated for 1 hour with biotinylated anti-
rabbit immunoglobulin G (1:1,000; Vector). Following several
PBS rinses, sections were incubated with ABC reagent (Vec-
tor) for 1 hour. Final visualization for NPY antibody was made
with nickel-enhanced 0.025% 3,3'-diaminobenzidine tetrahy-
drochloride (Sigma-Aldrich, Inc., St Louis, MO, USA) with
0.1% H2O2 as the chromogen.
Sections incubated with anti-VIP antibody were left overnight
before visualization with horseradish peroxidase-conjugated
Envision+® (Dako Cytomation, Carpinteria, CA, USA) with
diaminobenzidine as the chromogen.
All sections were counterstained in Richardson's stain, and
coverslipped with Assistent Histokitt (Assistant, Osterode,
Germany).
Negative controls
Controls of the specificity of the immunoreactions were rou-
tinely included by isotype control immunoglobulin incubation
and by preabsorption of the primary antibody with its respec-
tive antigen.
Evaluation of salivary gland inflammation
Salivary gland tissue sections from Taconic mice (n = 20) and
sections of submandibular glands in Group 2 (n = 14) were
evaluated to determine the degree of inflammation (Table 1).
Sections (5 μm) were obtained using a cryostat (Leica Instru-
ments, Nussloch, Germany) and were placed onto SuperFrost
Plus glass slides (Menzel, Braunschweig, Germany). Haema-
toxylin and eosin staining was performed, and evaluation was
performed in a representative section from each gland. Sali-
vary gland sections were evaluated and morphometrically ana-
lysed using a Leica DMLB light microscope connected to a
Color View III camera and Analysis software (Lucia v. 480;
Laboratory Imaging, Hostivaø, Czech Republic) or AnalySIS®
software (Soft Imaging System, GmbH, Münster, Germany), to
determine the focus score (that is, the number of foci compris-
ing ≥ 50 mononuclear cells/mm2 glandular tissue) and the ratio
index (that is, the ratio of the area of inflammation to the total
area of glandular tissue) [22,23].
Statistical analyses
Results are presented as the mean ± standard error of the
mean. Differences were tested between groups using the Stu-
dents t test or the Mann–Whitney rank sum test. P < 0.05 was
considered statistically significant.
Results
Blood flow responses to parasympathetic stimulation; 
effect of L-NAME (Group 1)
Baseline perfusion values were lower in NOD mice than
BALB/c mice (128 ± 14 PU and 221 ± 22 PU, respectively;
P = 0.002) (Figure 1), whereas the systemic blood pressure
was higher in the NOD mice (69 ± 16 mmHg, n = 10) than in
the BALB/c group (54 ± 16 mmHg, n = 10) although the dif-
ference was not significant (P = 0.054).
When the parasympathetic nerve to the glands was stimu-
lated, the maximal responses in glandular blood flow were sig-
Figure 1
Individual glandular blood flow responses to parasympathetic nerve stimulation
stimulation. Individual glandular blood flow measurements in perfusion 
units (PU) before (filled symbols) and after (open symbols) parasympa-
thetic nerve stimulation of the BALB/c mice and nonobese diabetic 
(NOD) mice (Taconic Bomholtgård, Group 1). Also shown are mean ± 
standard error of the mean values for each group. *P < 0.005 when 
comparing the same experimental condition in BALB/c mice and NOD 
mice.Page 4 of 12
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(Figure 1). In the BALB/c group the maximal responses aver-
aged 656 ± 90 PU, compared with 319 ± 48 PU in the NOD
group (Figure 1, P = 0.004) When L-NAME was administered
a reduced blood flow response to parasympathetic stimulation
was recorded in both groups as well (Figure 2). In BALB/c
mice the mean reduction was -51 ± 5% PU, compared with -
31 ± 3% PU in the NOD mice (P = 0.011, Figure 3).
Blood flow responses to muscarinic receptor activation 
by pilocarpine (Group 2)
Baseline perfusion values averaged 202 ± 17 PU and 261 ±
22 PU (P = 0.06, Figure 4a), and the systemic blood pressure
was 67 ± 17 mmHg and 61 ± 15 mmHg (P = 0.52, n = 7) in
NOD mice and BALB/c mice, respectively.
Immediately following pilocarpine infusion, an increase in
blood flow was observed in both groups of animals. The
increase averaged 181 ± 67 PU and 100 ± 44 PU, giving a
maximal response of 442 ± 104 PU and 306 ± 83 PU in
BALB/c mice and NOD mice, respectively (Figure 4a). The
maximal blood flow responses (Figure 4a) as well as blood
flow increases (Figure 4b) were significantly different between
the groups (P = 0.02).
Stimulated salivary secretion capacity
Salivary secretion after pilocarpine administration (0.05 μl/g
BW) in the NOD mice from Taconic (n = 6) averaged 0.41 ±
0.15 μl/min/g, and in the BALB/c mice (n = 5) averaged 0.54
± 0.18 μl/min/g. The difference was not statistically significant
(P = 0.21).
In NOD mice from Jackson Laboratories (Group 2) a signifi-
cant hyposecretion was found after pilocarpine administration
(0.1 μl/g BW), compared with the BALB/c mice. The average
secretion in BALB/c was 1.3 ± 0.33 μl/min/g, compared with
0.65 ± 0.16 μl/min/g in NOD mice (P = 0.001) (Figure 4c).
Localization of M3R in submandibular glands
Double labelling of CD31 and M3R revealed M3R in the wall
of blood vessels in submandibular glands of both NOD mice
and BALB/c mice (Figure 5a,b). In addition, M3R staining was
Figure 2
Responses in glandular blood flow after parasympathetic nerve stimulation and Nω-nitro-L-arginine-methyl ester infusion. (a) to (d) Original measure-
ments in perfusion units (PU) (a, c) before and (b, d) after Nω-nitro-L-arginine-methyl ester L-NAME) infusion in (a, b) a BALB/c mouse and (c, d) a 
NOD mouse (Taconic Bomholtgård, Group 1). Start of electrical stimulation indicated by arrows (2 ms at 7 Hz, 8 V, 2 to 5 s).Page 5 of 12
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blood vessels were usually seen adjacent to ducts in the sub-
mandibular glands of both strains (Figure 5a,b).
Distribution of autonomic nerve fibres
Immunohistochemical labelling of the submandibular gland tis-
sue revealed thin VIP-positive nerve fibres surrounding blood
vessels, and acinar and ductal epithelium, as illustrated in Fig-
ure 6a to 6c. The nerve fibres were seen throughout the glan-
dular parenchyma, frequently surrounding the acinar epithelial
cells. In areas surrounding the focal infiltrates, the staining pat-
tern of the submandibular glands from NOD mice resembled
that of BALB/c mice. VIP-positive nerve fibres were absent,
however, from areas of focal infiltrates (Figure 6b).
In contrast to VIP, NPY fibres were only detected around
blood vessels, striated ducts and collecting ducts (Figure
7a,b,d). Around blood vessels, typically located close to col-
lecting ducts, the NPY fibres formed plexuses (Figure 7d).
Interestingly, immunolabelling for both NPY (Figure 7c) and
VIP were observed in striated duct cells and may represent
endogenous production of neuropeptides in these cells. Per-
sisting blood vessels and ducts with innervating NPY fibres
could still be detected in the inflammatory infiltrates (Figure
7b).
Inflammation of the submandibular glands
Focal mononuclear cell infiltrates were observed in all salivary
gland tissue samples from NOD mice, and ranged from 4 to
17 in Taconic mice and from 4 to 9 in Jackson mice. No such
foci could be detected in the submandibular glands obtained
from any BALB/c mice. The focus score in the NOD mice aver-
aged 0.76 ± 0.09 and 0.63 ± 0.08, and the ratio index aver-
aged 0.035 ± 0.005 and 0.018 ± 0.003 in animals from
Taconic and Jackson Laboratories, respectively.
Discussion
The NOD mouse strain manifesting focal mononuclear cell
infiltrates and reduced stimulated saliva secretion is frequently
used as a model for SS. The fluid component in saliva derives
from the bloodstream, and blood flow in the salivary glands is
tightly regulated by autonomic nerves. During parasympathetic
nerve stimulation, vasodilatation and increased capillary blood
pressure leads to increased filtration of fluid out of the glandu-
lar capillaries into the interstitial space before it is secreted as
saliva by the glandular epithelium [24]. In patients with SS, the
saliva secretion from the submandibular and sublingual glands
is most severely affected [25]. Reduced blood flow responses
to secretory stimulation has been reported in patients with SS,
and may contribute to the reduced stimulated salivary gland
output in this group of patients [26].
Functional blood flow studies have previously not, to our
knowledge, been performed in NOD mice. In the present
study, reduced responses to parasympathetic stimulation and
to muscarinic receptor stimulation were recorded in sub-
mandibular glands in NOD mice compared with nondiseased
controls (BALB/c mice). Our results indicate that NOD mice
share the abnormal blood flow responses to parasympathetic
stimulation described in SS patients. The altered blood flow
responses in 17-week-old NOD mice (Group 2) observed
after pilocarpine infusion were followed by a reduced salivary
flow in this study. Whether changes in blood flow responses
are aggravated and thereby cause or contribute to a more pro-
nounced reduction in salivary flow later in the disease process
is still elusive and needs further investigation. NOD mice from
both suppliers developed focal infiltrates in the submandibular
glands, whereas only the NOD mice from Jackson Laborato-
ries revealed significantly lower salivary secretion rates as
compared with BALB/c mice. Both colonies of NOD mice
have been reported to develop hyposalivation as a conse-
quence of salivary gland inflammation, but the Taconic animals
develop hyposecretion [3] later in life than the Jackson Labo-
ratories mice [27].
Inflammatory cytokines and chemokines can activate vascular
cells and are suggested to be involved in atherogenesis [28].
In autoimmune diseases, vascular cells can actively contribute
to the inflammatory cytokine-dependent network in the blood
vessel wall. By interaction with invading cells, the activation
may contribute to development of atherosclerosis and
endothelial dysfunction [28]. The endothelial dysfunction may
cause altered blood flow responses [29]. Whether such a dys-
function is a mechanistic factor for the impaired vascular
response observed in NOD mice, however, is not known. A
potential effect of diabetes in vascular disease development in
Figure 3
Effect of Nω-nitro-L-arginine-methyl ester infusion on glandular blood flow responses after parasy pathetic nerve timulation
flow responses after parasympathetic nerve stimulation. Mean ± SEM 
glandular blood flow response (GBF) after parasympathetic nerve stim-
ulation (%). Black columns, measurements before Nω-nitro-L-arginine-
methyl ester (L -NAME) infusions; grey columns, measurements after L-
NAME treatments. *P < 0.02 when comparing the difference between 
BALB/c mice and nonobese diabetic (NOD) mice.Page 6 of 12
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using prediabetic mice.
Since part of the vasodilatation following parasympathetic
nerve stimulation in salivary glands is mediated through NO
release [30,31], we used a general inhibitor for NO synthesis
(L-NAME) to elucidate whether endothelial dysfunction in sub-
mandibular glands is evident in NOD mice. Our results show
that L-NAME treatment gave less reduction in blood flow
responses to parasympathetic stimulation in NOD mice com-
pared with BALB/c mice (Figures 2 and 3). This finding may
indicate an endothelial dysfunction associated with a reduced
NO synthesis activity in endothelial cells in NOD mice. L-
NAME has also been demonstrated to have binding affinity to
muscarinic receptors, and thereby acts as a muscarinic antag-
onist in addition to the ability to inhibit NO synthase [32]. It is
therefore possible that part of the L-NAME effect observed in
this study is due to a direct blocking of the muscarinic recep-
tor. Consequently, a reduced blocking effect by L-NAME in
NOD mice can at least in part be explained by changes in mus-
carinic receptor signalling. If this is the case, it provides sup-
port to the reduced effect in blood flow response observed
after muscarinic receptor activation by pilocarpine in NOD
mice.
Previous studies have shown alterations and progressive loss
of NO synthesis activity in submandibular glands in NOD mice
[16]. NO production by the vascular endothelium maintains an
Figure 4
Effects of pilocarpine infusion on glandular blood flow and salivary flow rate. (a) Parallel individual glandular blood flow measurements, (b) mean 
increase in glandular blood and (c) salivary flow after pilocarpine infusion (0.1 mg/100 g body weight) in BALB/c and nonobese diabetic (NOD) 
mice (Jackson Laboratories, Group 2). (a) Glandular blood flow is measured in perfusion units (PU) before (filled symbols) and after (open symbols) 
pilocarpine infusion. (b, c) Also shown are mean ± standard error of the mean values for each group. BALB/c mice (n = 7, black columns) and NOD 
mice (n = 7, grey columns). *P < 0.05, **P < 0.005 when comparing the same experimental conditions in BALB/c mice and NOD mice.Page 7 of 12
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including prevention of leukocyte–endothelial cell interactions
probably mediated by downregulation of P-selectin [33].
Endothelial dysfunction with reduced NO production in the
submandibular gland may contribute to the recruitment of
inflammatory cells in SS. The endothelial dysfunction observed
as reduced NO signalling in NOD mice may have contributed
to the accumulation of inflammatory cells observed as focal
mononuclear cell infiltrates.
It is also possible that NO has a basal tone on the vessels in
the gland, and that a reduction in NO production can explain
the relatively lower output values observed in basal blood flow
in the submandibular gland in NOD mice compared with
BALB/c mice.
In the current study we demonstrate for the first time the pos-
sible existence of M3R located in the blood vessel wall of the
salivary gland in NOD mice. When the parasympathetic nerve
innervating the gland is stimulated, acetylcholine and neu-
ropeptides are released and bind to their corresponding
receptors. In the salivary gland, muscarinic receptors are local-
ized in blood vessels, myoepithelial cells, and acinar and duc-
tal epithelial cells [13,34,35]. In a recent study, however, the
suitability of muscarinic acetylcholine receptor antibodies for
immunohistochemistry was evaluated on sections from recep-
tor gene-deficient mice, and the results demonstrated uncer-
tain specificity of muscarinic receptor subtype localization in
tissue sections [36]. The use of preabsorbtion of the primary
antibody with its respective antigen did not detect the nonspe-
cificity, and the authors suggest that it might be due to
stretches of amino acid sequences shared between two pro-
teins. The phenomena often occur among members of a pro-
tein family or receptor isoforms. The results demonstrate that
precautions must be taken when antibodies toward mus-
carinic receptors subtypes are utilized, and the detection of
positive immunolabelling is not a final proof that this subtype
of receptor is localized in the tissue.
Functional studies in rat parotid gland indicate that the vasodil-
atation in salivary glands may be mediated at least in part via
muscarinic M3R [37]. The M3R density on acinar cells is
reported to be altered in SS [11], and autoantibodies to the
receptors can be detected in patients [38] as well as in NOD
mice [12]. Contractile carbachol responses in smooth muscle
cells were shown recently to be lower in NOD mice with circu-
lating anti-M3R autoantibodies than in NOD mice lacking the
same autoantibodies [39]. These results support the hypothe-
sis that chronic stimulation of membrane-bound M3R can
result in receptor desensitization leading to reduced
responses. The similarly reduced blood flow responses after
both parasympathetic nerve stimulation and pilocarpine infu-
sion in this study may be explained by circulating autoantibod-
ies, muscarinic receptor desensitization and/or reduced
receptor density on the blood vessels walls. Another possible
explanation is a defect in the intracellular signalling of target
cells after muscarinic activation. Our finding indicates that the
innervation of blood vessels by autonomic nerves is normal in
NOD mice, supported by the notion that no visible differences
were observed in the distribution of NPY and VIP immunore-
Figure 5
Localization of muscarinic 3 receptor in the walls of blood vessels in salivary glands. Fluorescent staining of CD31+/M3R+ blood vessels in repre-
sentative sections from submandibular glands of (top) a BALB/c mouse and (bottom) a nonobese diabetic (NOD) mouse (Jackson Laboratories, 
Group 2). Images showing M3R+ staining (arrows) in the wall of CD31+ blood vessels (arrowheads). M3R+ acini cells (upper) and duct (lower) are 
also shown (arrows). Right images are merged. Scale bars = 50 μm. M3R, muscarinic 3 receptor; d, duct; v, vessel.Page 8 of 12
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NOD strains studied.
Reduced VIP concentrations in the submandibular gland of
NOD mice have previously been reported together with
reduced salivary secretion in response to VIP infusion [8],
leading to the conclusion of a likely defective receptor mecha-
nism leading to reduced neurotransmitter responsiveness. We
did not, however, observe differences in VIP staining of blood
vessels in the NOD mice compared with the BALB/c mice.
VIP-positive nerve fibres could not be detected in areas infil-
trated by inflammatory cells, whereas in all other areas the
innervation pattern resembled that observed in BALB/c mice
(Figure 5b). This observation is in line with observations in SS
patients where VIP fibres are depleted from central areas of
focal lymphocytic infiltrates [9,40].
A tropic effect of VIP on salivary gland parenchyma has been
postulated [40], and it is speculated whether the loss of inner-
vation in areas of focal infiltrates is the forerunner of acinar epi-
thelial cell atrophy in such areas. Our results in the present
Figure 6
Distribution of vasoactive intestinal peptide-immunoreactive nerve fibres in submandibular glands. Light microscopic view of vasoactive intestinal 
peptide (VIP)-immunoreactive (IR) fibres in submandibular gland tissue from (a), (c) a BALB/c mouse and (b) a nonobese diabetic (NOD) mice from 
Taconic Bomholtgård (Group 1). (a) Thin varicose fibres making a network in a blood vessel wall (arrowheads) in the central part of the gland. (b) 
VIP-IR fibres (arrowheads) in close proximity to acinar epithelial cells outside a focus of mononuclear cells. Note that the area of mononuclear cells 
lacks immunoreactivity to VIP. (c) A salivary duct supplied with thin VIP-IR fibres (arrows). (d) Control section from a NOD mouse after preabsorption 
of antibody with antigen. Scale bars = 50 μm. a, acinar cells; f, focus.Page 9 of 12
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observe any VIP fibres in areas of focal infiltration.
VIP stimulates and potentiates salivary secretion in normal
mice, but this ability is progressively lost in NOD mice [41].
Part of the VIP signalling effect is mediated by the NO/cGMP
pathway, and VIP failed to increase cGMP in 14-week-old and
16-week-old NOD mice [41]. This finding leads to the conclu-
sion that the reduced response to VIP is possibly due to a
defect in the VIP-mediated signalling in the secreting cells.
Immunostaining of both VIP and NPY was observed in striated
ductal epithelial cells (Figure 7c) in BALB/c and NOD sub-
mandibular glands. The role of this endogenous production of
neuropeptides is unknown and requires further investigation.
NPY has been observed close to the basal membrane in aci-
nar epithelial cells in rat salivary glands [42], and seems to be
of parasympathetic origin since they are significantly reduced
after parasympathetic denervation [43]. In mouse submandib-
ular glands, however, NPY-immunoreactive fibres are found
only in the wall of blood vessels and ducts (Figures 7a,b,d).
This finding supports the concept of two separate populations
Figure 7
Immunolabelling of neuropeptide Y in blood vessels and ductal epithelium in the submandibular glands. Immunostaining with anti-neuropeptide Y 
(anti-NPY) antibody in sections from (a), (b), (d) nonobese diabetic (NOD) submandibular gland and (c) BALB/c submandibular gland (Taconic 
Bomholtgård mice, Group 1). Scale bars = 50 μm. (a) Numerous NPY-immunoreactive (IR) fibres (arrowheads) in walls of blood vessels in areas 
with focal mononuclear cell inflammation. (b) Immunoreactivity (arrowheads) in the wall of a blood vessel and a duct surrounded by a focus of infil-
trating mononuclear cells. (c) Ductal cells showing intracellular NPY staining (arrowheads), whereas acini cells are without staining and lack innerva-
tion of NPY-IR fibres. (d) Typical localization of a vessel with a network of NPY-IR fibres in close proximity to a large duct (D) and a focus of infiltrating 
cells. a, acini; d, duct; f, focal mononuclear cell inflammation; v, vessel.Page 10 of 12
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involved in the control of blood flow, and the other associated
with control of secretion. NPY was not found in parasympa-
thetic fibres innervating acinar cells in submandibular salivary
glands in NOD mice or BALB/c mice, and hence is seemingly
uninvolved in the pathogenesis of acinar cell atrophy observed
in SS.
Conclusion
The NOD mouse is frequently used as an experimental model
of SS, and the present study shows that the changes in distri-
bution of parasympathetic nerves correspond with those
observed in salivary glands in patients with SS. Furthermore,
the present study provides new evidence of the pathogenesis
of SS by demonstrating impaired blood flow responses in sub-
mandibular glands in NOD mice after parasympathetic nerve
stimulation and muscarinic receptor activation. The latter was
followed by a parallel reduction in salivary flow. The study also
demonstrates dysfunctional endothelium with reduced NO
signalling after parasympathetic stimulation in the NOD mice.
The possible presence of M3R in the vasculature, reduced
blood flow responses and salivary secretion to muscarinic
receptor activation support the notion that M3R autoantibod-
ies present in NOD mice might critically impair fluid transport
required for salivation.
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